Novel Oral Anticoagulants in Renal Transplant Recipients: A Retrospective Cohort Study

1. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). Eur Heart J 2016; 37: 2893–2962.10.1093/eurheartj/ehw210Search in Google Scholar

2. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467–1507.10.1093/europace/euv309Search in Google Scholar

3. Connolly SJ, Ezekowitz MD, Yusuf S et al. RELY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–115.10.1056/NEJMoa0905561Search in Google Scholar

4. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–2104.10.1056/NEJMoa1310907Search in Google Scholar

5. Vanhove T, Spriet I, Annaert P et al. Effect of the direct oral anticoagulants rivaroxaban and apixaban on the disposition of calcineurin inhibitors in transplant recipients. Ther Drug Monit 2017; 39: 77–82.10.1097/FTD.0000000000000356Search in Google Scholar

6. Lam E, Bashir B, Chaballa M, Kraft WK. Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy. Expert Rev Clin Pharmacol 2019; 12(8): 781–790.10.1080/17512433.2019.1637733Search in Google Scholar

7. Bukhari MA, Al-Theaby A, Tawhari M, et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation. World J Transplant 2019; 9(6): 134–144.10.5500/wjt.v9.i6.134Search in Google Scholar

8. Zaleski M, Dabage N, Paixao R, Muniz J. Dabigatran-induced hyperkalemia in a renal transplant recipient: a clinical observation. J Clin Pharmacol 2013; 53(4): 456–458.10.1002/jcph.21Search in Google Scholar

9. Ryan M, Ware K, Qamri Z, et al. Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. Nephrol Dial Transplant 2014; 29(12): 2228–2234.10.1093/ndt/gft380Search in Google Scholar

10. Leon J, Sabbah L, Aubert O, et al. Efficacy and safety of direct oral anticoagulants in kidney transplantation: a single-center pilot experience [published online ahead of print, 2020 Feb 10]. Transplantation. 2020; 10.10.1097/TP.0000000000003168Search in Google Scholar

11. Möricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010 Feb; 24(2): 265–84.10.1038/leu.2009.257Search in Google Scholar

12. Lauten M, Möricke A, Beier R, et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica. 2012 Jul; 97(7): 1048–56.10.3324/haematol.2011.047613Search in Google Scholar

13. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: a Children’s Oncology Group Report. Leukemia. 2010 Feb; 24(2): 285–97.10.1038/leu.2009.262Search in Google Scholar